15 DHC 2023

25 - 27 January 2023
Wednesday 25 January
Athene B/C
09:30 - 10:30
Future (immune) therapies in Multiple Myeloma (Dutch spoken)

Moderator: Dr. R. Oostvogels

09:30 - 10:30
Future (immune) therapies in Multiple Myeloma
Speakers:
Dr. I. Nijhof,
Dr. W.J. Plattel
Room 15
09:30 - 10:30
Clinical Abstracts
Moderators:
Drs. K. Chuwonpad ,
Dr. M. Corsten
09:30 - 09:45
SARS-CoV-2 mRNA vaccination in AA
Speaker:
C. Pothast
09:45 - 10:00
Discordant Cellular and Humoral Responses to COVID-19 Vaccination in Hematology Patients
Speaker:
Q. Hofsink
10:00 - 10:15
Physical, Mental, and Social Health after allo-HSCT for SCD
Speaker:
E. Dovern
10:15 - 10:30
Mitapivat treatment for sickle cell disease
Speaker:
M. van Dijk
Room 4/5
09:30 - 10:30
Immunology Abstracts
Moderators:
dr. P. van Balen,
Dr. C.H.M.J. van Elssen
09:30 - 09:45
Generating human type 3 innate lymphoid cells to prevent graft-versus-host disease
Speaker:
J. Van der Meer
09:45 - 10:00
Targeting CD45 in mismatched HLA-DP to treat patients after alloSCT
Speaker:
N.E. Struckman
10:00 - 10:15
The role of HO-1 in acute GvHD
Speaker:
M. Verheij
10:15 - 10:30
A role for GATA2 in ILC development
Speaker:
Y.F. van Lier
Room 6/7
09:30 - 10:30
Lymphoid Abstracts
Moderators:
Dr. M.D. Levin,
dr. Y. Serroukh
09:30 - 09:45
p53 as a surrogate marker for TP53 mutational analysis
Speaker:
L. de Haan
09:45 - 10:00
Contrasting early and late genetic drivers of CLL
Speaker:
P. M. Kolijn
10:00 - 10:15
The proteome of untreated CLL
Speaker:
P. Hengeveld
10:15 - 10:30
A novel lymph node-based CLL 3D culture
Speaker:
M.V. Haselager
Foyer
10:30 - 11:00
Coffee / tea break
Athene B/C
11:00 - 12:00
How to treat - Bone marrow failure (Dutch spoken)

Moderator: 
Prof. dr. H.G.P. Raaijmakers

11:00 - 12:00
Bone marrow failure
Speakers:
Dr. A. Mohseny,
Dr. J.M.L. Tjon
Room 15
11:00 - 12:00
Clinical Abstracts
Moderators:
Dr. M.R. Nijziel,
Dr. S. Schep
11:00 - 11:15
High Bleeding Rate in RBD Patients with Single Heterozygous Variants in Recessive Genes
Speaker:
S. Willems
11:15 - 11:30
Heavy menstrual bleeding in rare bleeding disorders: results from the RBiN study
Speaker:
D. Maas
11:30 - 11:45
Effect of previous INR control during VKA therapy on subsequent DOAC intake
Speaker:
T. Elling
11:45 - 12:00
Peritranfusional C1 inhibitor in severe complement mediated AIHA
Speaker:
M. Jalink
Room 4/5
11:00 - 12:00
Immunology Abstracts
Moderators:
dr. R. de Groot,
prof. dr. M.H.M. Heemskerk
11:00 - 11:15
Human T cells recognize HLA-DP-bound peptides in two orientations
Speaker:
S. Klobuch
11:15 - 11:30
Decreased mitochondrial metabolism as the driver of T-cell dysfunction in CLL
Speaker:
N.B. Goedhart
11:30 - 11:45
Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients
Speaker:
C.H.M.J. van Elssen
11:45 - 12:00
Improving the potency of gdTCR anti-CD3 Bispecifics using CD3 binding affinity properties
Speaker:
M.J.T. Nicolasen
Room 6/7
11:00 - 12:00
Lymphoid Abstracts
Moderators:
Dr. W.J. Plattel,
Dr. W.B.C. Stevens
11:00 - 11:15
Distinct tumor microenvironments in DLBCL subtypes
Speaker:
T. Noordenbos
11:15 - 11:30
Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37
Speaker:
A. van Spriel
11:30 - 11:45
Clonality and mutation analysis in LPL/WM patients associated with DLBCL transformation
Speaker:
B. Scheijen
11:45 - 12:00
Serum TARC levels indicate Hodgkin lymphoma years before diagnosis
Speaker:
A. Diepstra
Room 8/9
11:00 - 12:00
Meet the Expert - Oncode PACT: Accelerator for cancer research. Focus on CAR T cell therapy (Dutch spoken)
Moderators:
Dr. H. Dolstra,
Prof. dr. M.C. Minnema
11:00 - 11:12
What is OncodePACT
Speaker:
Prof. dr. J.H.E. Kuball
11:12 - 11:24
Pitch CAR T cohorts and biobanking
Speaker:
Prof. dr. M.C. Minnema
11:24 - 11:36
Pitch CAR T and 3D models
Speaker:
Dr. Z. Sebestyen
11:36 - 11:48
Pitch CAR T and Imaging
Speaker:
Dr. T. van Meerten
11:48 - 12:00
Pitch OncodePACT and DARE NL
Speaker:
Dr. H. Dolstra
Room 14
12:15 - 13:00
Meet the Expert - HLH
12:15 - 13:00
HLH (Dutch spoken)
Speakers:
Dr. S. van Dorp,
Dr. J.A.M. van Laar
Room 15
12:15 - 13:00
Meet the Expert - PLL
12:15 - 13:00
PLL (Dutch spoken)
Speaker:
Dr. M. Bellido
Room 3
12:15 - 13:00
Meet the Expert

Moderator: Dr. P. te Boekhorst

12:15 - 13:00
Is artificial intelligence ready to replace the pathologist? (Dutch spoken)
Speakers:
S. Dooper, MSc,
Dr. K.M. Hebeda
Room 4/5
12:15 - 13:00
Meet the Expert - CML
12:15 - 13:00
CML (Dutch spoken)
Speaker:
Dr. J.J.W.M. Janssen
Room 6/7
12:15 - 13:00
Meet the Expert - Clonale Hematopoiese
12:15 - 13:00
Clonale Hematopoiese (Dutch spoken)
Speaker:
Prof. dr. G.A. Huls
Foyer
13:00 - 14:00
Lunch
Athene B/C
14:00 - 15:30
Educational - MDS (Dutch spoken)
Moderators:
Prof. dr. J.H. Jansen,
Prof. dr. A.A. van de Loosdrecht
14:00 - 14:20
Diagnostics: WHO2022 and ICC2022
Speaker:
Prof. dr. A.A. van de Loosdrecht
14:20 - 14:40
Prognostics: IPSS-R and IPSS-M
Speaker:
Prof. dr. J.H. Jansen
14:40 - 15:10
How to treat low risk MDS in 2023
Speaker:
Dr. C. Alhan
15:10 - 15:30
How to treat high risk MDS in 2023
Speaker:
Dr. S. Langemeijer
Room 15
14:00 - 15:30
Clinical abstracts - lymphoid
Moderators:
Dr. M Jak,
Dr. S.H. Tonino
14:00 - 14:15
Tumor microenvironment and quantitative PET features in R/R Hodgkin lymphoma
Speaker:
J. Driessen
14:15 - 14:30
H100 study in ALL reanalyzed by multi-state modeling: benefits and risks of clofarabine
Speaker:
S. Hermans
14:30 - 14:45
Circulating tumor DNA as biomarker for large B-cell lymphoma of the sanctuary si
Speaker:
Y. Zhong
14:45 - 15:00
ITD followed by ixazomib or placebo in non-transplant newly diagnosed MM patients
Speaker:
M.R. Seefat
15:00 - 15:15
Immunogenicity of PCV13 Combined with PPSV23 in Patients with Chronic Lymphocytic Leukemia
Speaker:
I. Kant
15:15 - 15:30
HD-MTX-based treatment regimens and consolidation strategies in PCNSL
Speaker:
F. de Groot
Room 4/5
14:00 - 15:30
Myeloid Abstracts
Moderators:
Dr. V. van den Boom,
Dr. E. Brandsma
14:00 - 14:15
Low Voxelotor Concentrations Exacerbate Sickle Cell Formation At Low Oxygen Pressure
Speaker:
Dr. E. Brandsma
14:15 - 14:30
Neutrophil Function in Bone Marrow
Speaker:
S. Bongers
14:30 - 14:45
High and low myeloid skewing and the association with clonal hematopoiesis
Speaker:
M. van Bergen
14:45 - 15:00
Defining stress erythropoiesis in bone marrow
Speaker:
S. van der Meulen
15:00 - 15:15
GFI1B And LSD1 Repress A Myeloid Differentiation Program During iMK differentiation
Speaker:
J. Venhuizen
15:15 - 15:30
The use of iPSC models to study and treat hereditary anemias
Speaker:
C. Clark
Room 6/7
14:00 - 15:30
Lymphoid Abstracts
Moderators:
Dr. M. Bellido,
Dr. L.E. van der Wagen
14:00 - 14:15
Loss-of-adhesion CRISPR screen
Speaker:
M.F.M. de Rooij
14:15 - 14:30
Model of acquired resistance to DOT1L inhibition in KMT2A-rearranged ALL
Speaker:
P. Schneider
14:30 - 14:45
ZDHHC11 as a novel regulator of the MEF2B-BCL6 axis in Burkitt lymphoma
Speaker:
J. Kluiver
14:45 - 15:00
Phenotypic diversity in pediatric acute lymphoblastic leukemia is driven by asymmetric cell division of the cell of origin
Speaker:
V. Poort
15:00 - 15:15
AID impacts gene expression in DLBCL skewing cell-of-origin-associated gene profiles
Speaker:
L.H. Gijsbers
15:15 - 15:30
MLL (KMT2A)-Rearranged Acute Lymphoblastic Leukemias are Addicted to S-adenosylmethionine
Speaker:
T. Tee
Room 8/9
14:00 - 15:30
Masterclass Bone Marrow diagnostics (Dutch spoken)
Speakers:
Dr. E. Kramer,
Dr. W.B.C. Stevens,
Dr. M.J. Wondergem
Foyer
15:30 - 16:00
Coffee / tea break
Athene B/C
16:00 - 17:30
Educational - Vaccination guide line (Dutch spoken)

Moderator: Dr. A. Goorhuis

16:00 - 17:30
Vaccination Guideline
Speakers:
Dr. M.D. Hazenberg,
Dr. I. Nijhof
Room 15
16:00 - 17:30
Clinical Abstracts
Moderators:
Dr. D. de Leeuw,
Dr. E. Nur
16:00 - 16:15
HiDAC versus FLAG-IDA in relapsed AML
Speaker:
D. van der Tuin
16:15 - 16:30
KD mutations and clinical outcome in CML
Speaker:
C. Kockerols
16:30 - 16:45
High-dimensional immune profiling of MDS patients
Speaker:
D. van Ens
16:45 - 17:00
D-PCR for TFR prediction
Speaker:
C. Kockerols
17:00 - 17:15
Cardiovascular adverse events in AML patients treated with anthracyclines
Speaker:
J. Geels
17:15 - 17:30
Simulation of Interim Analyses within the HO132 trial using Bayesian inference
Speaker:
N. van der Maas
Room 4/5
16:00 - 17:30
Myeloid Abstracts
Moderators:
Dr. A. Marneth,
Dr. B. van der Reijden
16:00 - 16:15
The oncogene FTO is not overexpressed in NPM1mut AML
Speaker:
S. Arza Apalategi
16:15 - 16:30
Functional and molecular characterisation of subclones in AML patients
Speaker:
S. Hogeling
16:30 - 16:45
Origin and clonal evolution of pediatric t-MN
Speaker:
E. Bertrums
16:45 - 17:00
EVI1 drives AML by repressing CEBPA via a targetable interaction with CtBP1/2
Speaker:
D. Pastoors
17:00 - 17:15
Role of the polycomb protein CBX7 in AML
Speaker:
A. de Groot
17:15 - 17:30
High-Dimensional Imaging of the Bone Marrow in Acquired Aplastic Anemia
Speaker:
E. Pool
Room 6/7
16:00 - 17:30
Lymphoid Abstracts
Moderators:
Dr. R.W.J. Groen,
Dr. T. van Meerten
16:00 - 16:15
Targeting V-D-J recombined B-cell receptors as neoantigens for lymphoma immunotherapy
Speaker:
P. Greve
16:15 - 16:30
Using a Gene Signature as Predictive Biomarker of Response to Venetoclax in AL amyloidosis
Speaker:
N. van Nieuwenhuijzen
16:30 - 16:45
Therapeutic IgA for pediatric Non-Hodgkin lymphoma
Speaker:
C. Chan
16:45 - 17:00
Metabolic reprogramming of iPSC-derived T cells
Speaker:
A. Nianias
17:00 - 17:15
Oligomerization of the human chemokine receptor CXCR4 in hematological malignancies.
Speaker:
S. Mobach
17:15 - 17:30
No effect of vitamin C on neutrophil recovery in autologous SCT
Speaker:
G.N.Y. van Gorkom
Room 8/9
16:00 - 17:30
Masterclass Bone Marrow diagnostics (part 2, Dutch spoken)
Speakers:
Dr. E. Kramer,
Dr. W.B.C. Stevens,
Dr. M.J. Wondergem


Note for attendees: part 2 of this Masterclass can only be attended with a registration of attendency to part 1.

Foyer
17:30 - 18:00
Drinks
Athene B/C
18:00 - 19:00
Keynote lecture: Stem Cell Clonality and the Niche

Moderator: Dr. E.M. de Pater
Speaker: Dr. Leonard Zon

Foyer
19:00 - 20:00
Buffet
Room 15
09:00 - 10:30
Clinical abstracts - Transplantation
Moderators:
Dr. A.E.C. Broers,
Dr. L.M. Morsink
09:00 - 09:15
Donor CD4+ T cell infusion after allogeneic stem cell transplantation.
Speaker:
J.G.K. van der Hem
09:15 - 09:30
Graft engineering: how long can you wait, how low can you go, and pandemic readiness.
Speaker:
A. Stuut
09:30 - 09:45
Autologous vs Allogeneic SCT in patients with AITL
Speaker:
M. Aydin
09:45 - 10:00
Immune reconstitution after allogeneic stem cell transplantation guiding new opportunities
Speaker:
P. van Hauten
10:00 - 10:15
Azathioprine/Hydroxyurea Preconditioning Added to MSD-HSCT with Alemtuzumab/TBI for SCD
Speaker:
E. Dovern
10:15 - 10:30
induction prior to alloSCT does not improve OS in MDS
Speaker:
M. van Gelder
Room 4/5
09:00 - 10:30
Educational - Immuno-hematology - Transfusion (Dutch spoken)
Moderators:
Dr. V.M.J. Novotny ,
Dr. M.R. Schipperus
09:00 - 09:30
Platelet transfusions in ITP: ineffective or unexploited?
Speaker:
Dr. R. Kapur
09:30 - 10:00
Platelets in ITP; Victims in charge of their own fate.
Speaker:
Drs. V.S. Nelson
10:00 - 10:30
State of the art treatment ITP.
Speaker:
Dr. M.R. Schipperus
Room 6/7
09:00 - 10:30
Immunology Abstracts
Moderators:
Dr. S. van Dorp,
Dr. A. van der Waart
09:00 - 09:15
NKG2A deletion in NK cells promotes cytotoxicity and tumor infiltration
Speaker:
R. Klein Wolterink
09:15 - 09:30
Stem cell-derived natural killer cells as off-the-shelf immunotherapy for cancer
Speaker:
L. Hooijmaijers
09:30 - 09:45
Creating a favorable immune landscape to increase CD19 specific CAR T efficacy for treatme
Speaker:
N.M.M. Dautzenberg
09:45 - 10:00
The impact of c-MYC on the anti-tumor effect of immunotherapy strategies
Speaker:
V. de Jonge
10:00 - 10:15
Mechanisms of MSCs as drivers of the suppressive tumor microenvironment in leukemia
Speaker:
A. Meringa
10:15 - 10:30
Improving stem cell-derived natural killer cell immunotherapy against ovarian carcinoma with IL-15 transpresentation
Speaker:
M. Vidal Manrique
Room 8/9
09:00 - 10:30
Myeloid Abstracts
Moderators:
Dr. E.M. de Pater,
Dr. C.M. Woolthuis
09:00 - 09:15
Moleculary-defined De Novo AML and sAML are different entities
Speaker:
E. Boertjes
09:15 - 09:30
Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation st-
Speaker:
E. O. Karakaslar
09:30 - 09:45
Functional role of TP73 isoforms in AML
Speaker:
D. Pereira-Martins
09:45 - 10:00
Benefit of MRD Guidance in Intermediate-Risk AML Patients Compared to an Unguided Cohort
Speaker:
J. Tettero
10:00 - 10:15
Lipid nanoparticles as treatment for t(8;21) Acute Myeloid Leukaemia
Speaker:
L. Swart
10:15 - 10:30
Targeting sugarcoating in MPNs
Speaker:
A. Marneth
Sydneyzaal
09:00 - 10:30
Casuïstiek - WHO classification Lymphomas (Dutch spoken)
Moderator:
Dr. R. van Rijn


Panel:
Dr. R. Mous, dr. M. Nijland,
Dr. T. Snijders, dr. K. Lam,
Dr. A. Diepstra. 

09:00 - 09:30
Casus 1
Speakers:
Dr. J. van Doesum,
Dr. L. Koens
09:30 - 10:00
Casus 2
Speakers:
Dr. M. van den Brand,
Dr. W. Deenik
10:00 - 10:30
Casus 3
Speakers:
Dr. L. de Haan,
Dr. A. Sijs-Szabo
Foyer
10:30 - 11:00
Coffee / Tee Break
Room 4/5
11:00 - 12:30
Tips & Tricks: Hemostase, trombose (Dutch spoken)
Moderator:
Dr. M. Kruip
11:00 - 11:30
Bleeding tendency without Von Willebrand, what to do?
Speaker:
Dr. F. Heubel-Moenen
11:30 - 12:00
Anticoagulation and thrombocytopenia, what to do?
Speaker:
Dr. M. Lauw
12:00 - 12:30
Anticoagulation and pregnancy(s) wish, what to do?
Speaker:
Dr. M. Kruip
Room 6/7
11:00 - 12:30
Immunology Abstracts
Moderators:
Dr. C.E. Rutten,
Dr. M.A. de Witte
11:00 - 11:15
A multidimensional approach reveals adaptive immunity in pediatric AML
Speaker:
J.B. Koedijk
11:15 - 11:30
Bone marrow profiles of LR-MDS treated with Lenalidomide
Speaker:
C. Duetz
11:30 - 11:45
Targeting multiple myeloma-associated macrophages with NK cells and an anti-PDL1 antibody
Speaker:
N. Beelen
11:45 - 12:00
CD24: A potential immunotherapeutic target for Mantle Cell Lymphoma
Speaker:
J. Alvarez-Freile
12:00 - 12:15
Epigenetic and transcriptional regulation of CLL-induced CD4 T-cell dysfunction
Speaker:
F. Peters
12:15 - 12:30
VISTA is a negative innate immune regulator
Speaker:
Y. Lin
Room 8/9
11:00 - 12:30
Meet the Expert - (reprise)
11:00 - 11:45
CML (Dutch spoken)
Speaker:
Dr. J.J.W.M. Janssen

 

 

 

 

 

 

11:46 - 12:30
Clonale Hematopoiese (Dutch spoken)
Speaker:
Prof. dr. G.A. Huls
Sydneyzaal
11:00 - 12:30
Top of DHC - Best of ASH (Dutch spoken)
Moderators:
Prof. dr. N.M.A. Blijlevens,
Prof. dr. S. Zweegman
11:00 - 11:15
Prognostic value of FLT-3-ITD residual disease in acute myeloid leukemia
Speaker:
T. Grob
11:15 - 11:30
Patient preferences and experiences regarding TPO-RAs for ITP in the Netherlands
Speaker:
J.J. Zwaginga
11:30 - 11:45
High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
Speaker:
D. Hofste op Bruinink
11:45 - 12:00
Primary endpoint analysis of the H139 for previous untreated CLL
Speaker:
S. Kersting
12:00 - 12:15
FDG PET improves baseline clinical predictors of response in DLBCL: the HOVON-84 study
Speaker:
C. Burggraaff
12:15 - 12:30
IDD in frail patients, long term follow up with an emphasis on the maintenance phase
Speaker:
Dr. K. Groen
Foyer
12:30 - 13:30
Lunch
Athene B/C
13:30 - 14:30
Challenges and opportunities for integrated diagnostics in malignant hematology: an EHA and personal perspective

Moderator: Prof. dr. F.W.G. Leebeek
Speaker: Prof. dr. Elizabeth Macintyre

Room 11
14:30 - 15:30
Meet the expert - Oncode PACT: Accelerator for cancer research: Focus on CAR T therapie (Dutch spoken, reprise)
Moderators:
Dr. H. Dolstra,
Prof. dr. M.C. Minnema
14:30 - 14:42
What is OncodePACT
Speaker:
Prof. dr. J.H.E. Kuball
14:42 - 14:54
Pitch CAR T cohorts and biobanking
Speaker:
Prof. dr. M.C. Minnema
14:54 - 15:06
Pitch CAR T and 3D modellen
Speaker:
Dr. Z. Sebestyen
15:06 - 15:18
Pitch CAR T and Imaging
Speaker:
Dr. T. van Meerten
15:18 - 15:30
Pitch OncodePACT and DARE NL
Speaker:
Dr. H. Dolstra
Room 15
14:30 - 16:00
Clinical Abstracts
Moderators:
Dr. S.J. Bernelot-Moens ,
Dr. V.M.J. Novotny
14:30 - 14:45
End-of-life treatment and treatment costs of multiple myeloma patients in real-world
Speaker:
M.R. Seefat
14:45 - 15:00
Quality of life and geriatric assessment in CLL
Speakers:
M.D. Levin,
L. van der Straten
15:00 - 15:15
Outcomes for patients with relapsed or refractory DLBCL: a Dutch population-based study
Speaker:
E. Pennings
15:15 - 15:30
Long-term health related quality of life in DLBCL survivors compared to a norm population
Speaker:
S. Neppelenbroek
15:30 - 15:45
Outcome of Transformed Marginal Zone Lymphoma
Speaker:
J. Bult
15:45 - 16:00
Renal Toxicity after (R-)DHAP Chemotherapy
Speaker:
D. Kamp
Room 4/5
14:30 - 16:00
How to treat - AML (Dutch spoken)
Speakers:
Dr. M. Corsten,
Dr. B.J. Wouters
Room 8/9
14:30 - 16:00
Benigne Abstracts
Moderators:
Dr. I. van Moort,
Dr. M.A.E. Rab
14:30 - 14:45
The Nijmegen ultra-sensitive Bethesda Assay
Speaker:
M. Verhagen
14:45 - 15:00
Proteomic landscapes of inherited platelet disorders with different etiologies
Speaker:
I. Kreft
15:00 - 15:15
Phenotypic heterogeneity within healthy donor endothelial colony forming cells explored by morphological analysis and RNA expression profiling
Speaker:
S.N.J. Laan
15:15 - 15:30
ZO-2 in platelet-platelet interaction
Speaker:
C. Baaten
15:30 - 15:45
Novel diagnostic tools to estimate bleeding risk in patients with bleeding disorders.
Speaker:
R. Arisz
15:45 - 16:00
An EMM improves hydration and decreases adhesion of RBCs in sickle cell disease
Speaker:
M. van Dijk
Foyer
16:00 - 16:30
Coffee / Tea break
Athene B/C
16:30 - 17:30
Keynote Lecture : Cost in Healthcare (Dutch spoken)

Moderator: Dr. P. te Boekhorst
Speaker: Dr. E.J.O. Kompanje

Foyer
17:30 - 19:45
Buffet
Athene B/C
19:45 - 20:30
DHC jubileum - NEUROMAGIC, Nothing is what it seems to be...(Dutch spoken)
Speaker:
MINDF*CKER Victor Mids

Victor Mids is an illusionist and doctor (not practicing).
With this innovative combination he brings illusion and science together in a unique way

Centre Court
20:30 - 23:59
Social Program
Athene B
09:00 - 10:30
VHL (Dutch spoken)
Moderator:
Dr. M.V. Lukens
09:00 - 09:45
Pathophysiology and diagnostics of thrombotic microangiopathy
Speaker:
Dr. D. Meijer
09:45 - 10:30
WHO/ELN/ICC-Myeloid 2022: only molecular characterization matters?
Speaker:
Dr. A.B. Mulder
Athene C
09:00 - 10:30
Educational Multiple Myeloma- exhaustive possibilties, how great is that! or? (Dutch spoken)
Moderators:
Dr. M. Hoogendoorn,
Dr. E. van der Spek
09:00 - 09:20
Treatment; intensive or exhaustive in older non-fit patients?
Speakers:
Dr. P.A.F. Geerts,
Dr. K. Groen
09:20 - 10:05
So or too many possibilities to treat relapsed myeloma? How to overcome choice stress?
Speakers:
Dr. R. Oostvogels,
Drs. R. Wester,
Drs. P. Ypma
10:05 - 10:30
Running out of cash – what to do or not to do that is the question
Speakers:
Dr. H. Blommestein,
Prof. dr. S. Zweegman
Foyer
10:30 - 11:00
Coffee / tea break
Athene B
11:00 - 12:30
Coagulation (Dutch spoken)
Moderators:
Dr. L. Nieuwenhuizen,
Dr. L.F.D. van Vulpen
11:00 - 11:30
Rare coagulation disorders
Speaker:
Dr. S. Schols
11:30 - 12:00
Trombocytopathy
Speaker:
Dr. F. Heubel-Moenen
12:00 - 12:30
Antiphospholipid Syndrome
Speaker:
Dr. G. Jansen
Athene C
11:00 - 12:30
Joint session (HOVON-NVvH and patient associations; (Dutch spoken)

A challenging discussion with patients and hematologists about decision aid instruments within the hematology.

Moderators:
Dr. M. Eefting,
Dr. L. Tick,
Prof. dr. N.M.A. Blijlevens,
Dr. J. Mol

11:00 - 12:30
“Decision aid instruments: What is there to choose??”

 

Participants:
Prof. dr. N.M.A. Blijlevens,
Dr. M. Eefting,
Dr. L. Tick,
Dr. S. Kersting,
Dr. P. Geerts,
M. van Maarschalkenweerd PhD,
Dr. J. Mol

Foyer
12:30 - 13:30
Lunch
Room 6/7
12:30 - 13:30
Algemene Leden Vergadering NVvH (incl. lunch)
room 9
12:30 - 13:30
Algemene ledenvergadering JNVvh
Room 6/7
13:30 - 13:45
Award Ceremony
13:30 - 13:45
Jaap Steenbergen Stipendium
Speaker:
Follows later
Athene B/C
13:45 - 14:45
Grand Round
Speakers:
Dr. S.J. Bernelot-Moens ,
Dr. H. A.M. Kooistra
13:45 - 14:45
Expert panel

Drs. Y. Raz
Dr. R. van Rijn
Prof. dr. E.A.M. Beckers

×